TAK — Takeda Pharmaceutical Company Limited

Summary of Takeda's Q3 FY 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: JPY 3.4 trillion for the first nine months, down 3.3% year-on-year (2.8% decline at constant exchange rates).
• Core Operating Profit: JPY 971.6 billion, a decrease of 3.4% year-on-year.
• Reported Operating Profit: JPY 422.4 billion, an increase of 1.2%.
• Core EPS: JPY 428; Reported EPS: JPY 137.
• Adjusted Free Cash Flow: Strong at JPY 625.9 billion, despite a USD 1.2 billion upfront payment to Innovent Biologics.
• Growth Products: Over 50% of total revenue, growing 6.7% at constant exchange rates.

2. Strategic Updates and Business Highlights

• Product Pipeline: Focus on three key late-stage products expected to launch within 18 months:
  • Oveporexton: First orexin agonist for narcolepsy type 1, showing significant improvements in Phase III trials.
  • Rusfertide: Hepcidin mimetic for polycythemia vera, demonstrating durable hematocrit control.
  • Zasocitinib: TYK2 inhibitor for psoriasis, with promising Phase III data.
• Market Positioning: ENTYVIO Pen now covered by all major pharmacy benefit managers in the U.S., enhancing competitive positioning.
• Organizational Changes: Transition to new CEO Julie Kim, with a focus on operational efficiency and readiness for upcoming product launches.

3. Forward Guidance and Outlook

• Revised Revenue Guidance: Expected low single-digit decline at constant exchange rates, primarily due to VYVANSE generic erosion.
• Core Operating Profit and EPS Guidance: Maintained for the full year.
• Future Product Contributions: Anticipated contributions from new launches, with a focus on maintaining operational efficiency.

4. Bad News, Challenges, or Points of Concern

• VYVANSE Generic Erosion: Significant impact on revenue, although the decline is tapering off.
• Competitive Pressures: New entrants in the market affecting growth rates of products like TAKHZYRO and ENTYVIO.
• Market Dynamics: Slower growth in rare diseases and challenges in the albumin market due to softening demand in China.
• Potential Price Cuts: ENTYVIO selected for IRA price negotiations, raising concerns about future revenue projections.

5. Notable Q&A Insights

• Future Guidance: Management indicated that the next fiscal year's budget is still being finalized, with expectations for growth in new products but acknowledging the maturity of existing products.
• ENTYVIO's Market Position: Strong Q3 performance attributed to improved coverage, but long-term growth may stabilize rather than gain market share.
• Zasocitinib Launch Timing: Regulatory submission expected in summer 2025, with potential for earlier launch depending on FDA review.
• TAKHZYRO Performance: Slower growth attributed to competitive pressures and Medicare Part D redesign impacts.
• Organizational Changes: Focus on enhancing U.S. marketing effectiveness and readiness for product launches, with an emphasis on operational excellence.

This earnings call reflects Takeda's strategic focus on innovation and operational efficiency while navigating challenges in a competitive pharmaceutical landscape.